American International Group Inc.'s successful bid to avoid covering litigation against opioid manufacturing giant ...

The global extended release drugs market is experiencing significant growth, projected to expand at a robust 11% CAGR from 2022 to 2032. With a valuation of USD 48 billion in 2022, the market is ...

Mallinckrodt PLC, an Irish pharmaceutical company with a big footprint and long history in the St. Louis area, will buy U.S.

Mallinckrodt, the Irish pharmaceutical company with its U.S. headquarters in Hazelwood, has agreed to merge with drug maker ...

When the deal closes, Endo will become a wholly owned subsidiary of Mallinckrodt. The combined company will take on a ...

Pharmaceutical companies Mallinckrodt Pharmaceuticals Plc and Endo Inc. have signed an agreement to create a combined company worth $6.7 billion. This is reported in a joint press release. Under the ...

Mallinckrodt and Endo plan to combine their generic pharmaceuticals businesses and Endo's sterile injectables business after ...

(Whitney Curtis/AP Images for Mallinckrodt, File) Ireland’s Mallinckrodt will buy U.S. drugmaker Endo in a cash-and-stock deal valued at $6.7 billion. The companies said Thursday that Endo ...

The pairing of Mallinckrodt plc and Endo Inc. is expected to create a pharma heavyweight that will generate $3.6 billion in 2025 revenue after the duo combines their generic pharmaceuticals businesses ...

Mallinckrodt and Endo , drugmakers which recently emerged from bankruptcy after a wave of U.S. opioid lawsuits, announced ...

EAST WHITELAND — Endo, a pharmaceutical company that has its global headquarters in Chester County, is being acquired by Ireland’s Mallinckrodt in a cash-and-stock deal valued at $6.7 billion.

Drugmaker Mallinckrodt struck a deal to buy Endo in an effort to build a diversified pharmaceuticals company with a hefty U.S. footprint. The companies said Thursday they reached a definitive ...